LUNG Earnings Prediction
The chart below shows how LUNG performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LUNG sees a +3.92% change in stock price 10 days leading up to the earnings, and a -3.14% change 10 days following the report. On the earnings day itself, the stock moves by -1.31%. This data can give you a slight idea of what to expect for the next quarter's release.
LUNG Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
20.39M
15.39%
-1.91%
Gross Margin
73.70%
-0.05%
0.07%
Operating Margin
-69.30%
-19.32%
3.45%
Net Margin
-69.38%
-17.73%
-5.91%
EPS
-0.36
-7.69%
-7.69%
No Data Available
LUNG Earnings Analysis
Pulmonx Corporation Common Stock Corporation (LUNG.O) Earnings Conference Call
Positive
Worldwide Revenue Increase: Total worldwide revenue for the 3 months ended September 30, 2024, was $20.4 million, a 15% increase over the prior year period and also an increase of 15% on a constant currency basis.
U.S. Revenue Increase: U.S. revenue in the third quarter was $13.8 million, a 17% increase over the prior year period.
International Revenue Increase: International revenue in the third quarter of 2024 was $6.6 million, an increase of 12% over the prior year period and also an increase of 12% on a constant currency basis.
Active Accounts Increase: We were pleased by the increase in the number of active accounts in Q3, ending the quarter with 280 active accounts, an addition of 15 new accounts in the U.S.
2024 Revenue Forecast: We expect to deliver fully year 2024 revenue in the range of $81 million to $84 million, representing approximately 20% growth at the mid-point.
Negative
Operating Expenses Increase: Total operating expenses for the third quarter of 2024 were $29.2 million, an increase of 3% over the prior year period.
Stock-Based Compensation Expense: Non-cash stock-based compensation expense was $5.4 million in the third quarter of 2024.
Operating Expenses Increase: Excluding stock-based compensation expense, total operating expenses in the third quarter of 2024 increased by 5% over the prior year period.
Quarterly Net Loss Comparison: Net loss for the third quarter of 2024 was $14.1 million or a loss of $0.36 per share compared to a net loss of $14.9 million or a loss of $0.39 per share for the same period of the prior year.
EBITDA Loss Improvement: Adjusted EBITDA loss for the third quarter of 2024 was $8.1 million as compared to $9 million in the third quarter of 2023, a 10% improvement on a year-over-year basis.
LUNG FAQs
How does LUNG typically perform around its earnings report dates?
Is Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LUNG Earning Call Sentiment
Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LUNG.O
0.66%Positive
The earnings call presents a mixed picture: strong sales growth and a maintained cash position are positive, but ongoing net losses and increased operating expenses are concerning. The reiterated guidance suggests stability but not significant growth. The Q&A reveals confidence in the current guidance but hesitance to provide future growth specifics, adding uncertainty. Regulatory and market competition risks are noted, and while international expansion shows promise, it remains a longer-term prospect. Overall, the sentiment is balanced, leading to a neutral stock price prediction.